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Abstract  
Background: Clinical observations are suggesting accelerated granulation tissue formation in 
traumatic wounds treated with Vacuum-Assisted Closure (VACTM). Aim of this study was to 
determine the impact of VAC™ therapy versus alternative Epigard™ application on local 
inflammation and neovascularization in traumatic soft tissue wounds. 
Methods: 32 patients with traumatic wounds requiring temporary coverage (VAC™ n=16; 
Epigard™ n=16) were included. At each change of dressing, samples of wound fluid and 
serum were collected (n=80). The cytokines interleukin (IL)-6, IL-8, Vascular Endothelial 
Growth Factor (VEGF) and Fibroblast Growth Factor (FGF)-2 were measured by ELISA. 
Wound biopsies were examined histologically for inflammatory cells and degree of 
neovascularization present. 
Results: All cytokines were found to be elevated in wound fluids during both VAC™ and 
Epigard™ treatment, whereas serum concentrations were negligible or not detectable. In 
wound fluids, significantly higher IL-8 (p<0.001) and VEGF (p<0.05) levels were detected 
during VAC™ therapy. Furthermore, histological examination revealed increased 
neovascularisation (p<0.05) illustrated by CD31 and von Willebrand Factor (vWF) 
immunohistochemistry in wound biopsies of VAC™ treatment. In addition, there was an 
accumulation of neutrophils as well as an augmented expression of VEGF (p<0.005) in 
VAC™ wound biopsies.  
Conclusion: This study suggests that VAC™ therapy of traumatic wounds leads to increased 
local IL-8 and VEGF concentrations, which may trigger accumulation of neutrophils and 
angiogenesis and thus, accelerate neovascularization.  
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Introduction 
The management of traumatic wounds remains a major challenge in surgery. A variety of 
methods of temporary wound closure have been described and used in the past. Among 
current standards is wound coverage by Epigard™ (Biovision GmbH, Ilmenau, Germany) or 
by Vacuum-Assisted Closure (VAC™, Kinetic Concepts, Inc., San Antonio, TX, USA) (Figs. 
1A and B). Epigard™ is a two-layer, non-medicated wound dressing which approximates the 
function of human skin (Fig. 1A).1 The superficial Teflon layer is permeable to air, however, 
prevents the penetration by bacteria and fluids from the outside. The lower layer is made from 
polyurethane. It is adhesive to the wound exudates and wound ground. Thus, removal of the 
Epigard™ produces mechanical debridement of the wound. The VAC™ therapy is a 
temporary protection of soft tissue defects by polyurethane foam which is sealed with a 
transparent adhesive drape (Fig. 1B). A negative topical pressure within the wound is then 
generated using a vacuum pump.2 VAC™ therapy has been described to be beneficial for the 
wound management in a variety of clinical traumatic and non traumatic soft tissue defects.2 
This corroborates our clinical observation of improved wound healing of traumatic wounds 
after VAC™ therapy compared with application of alternative wound dressings e.g. 
Epigard™. It has been shown that VAC™ therapy, on the one hand, optimizes micro 
perfusion and blood flow, increases the partial oxygen pressure within the tissue and reduces 
bacterial colonialization.2 The cyclical application of sub-atmospheric pressure, on the other 
hand, alters the cytoskeleton of the cells in the wound bed triggering a cascade of intracellular 
signals that increases the rate of cell division and subsequent formation of granulation tissue.2 
However, the exact mechanisms leading to this improved wound healing remain largely 
unknown. 
 During each of the three phases of wound healing, inflammation, proliferation and scar 
formation, local cellular and circulating humoral components play an important role.3-7 
Among the latter, interleukin (IL)-6 has been described as a pro- and anti-inflammatory 
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mediator.8 It is a potent inducer of B-cell differentiation and immunoglobulin synthesis as 
well as acute phase protein expression by hepatocytes. In local trauma, increased IL-6 levels 
have been demonstrated in wound fluids compared with matched serum.3 Interleukin(IL)-8 is 
a leukocyte specific chemoattractant cytokine and seems to play an important role for the 
recruitment of polymorphonuclear neutrophils (PMN) during the early inflammation phase of 
wound healing.9 In addition, IL-8 is also involved in the activation of leukocytes during the 
tissue repair phases.10 PMN have recently been shown to express vascular endothelial growth 
factor (VEGF), and following traumatic brain injury, an early increase in VEGF expression 
was described within 4 hours post-injury in the traumatized parenchyma associated with 
invasion of neutrophils granulocytes.11,12 VEGF is a growth factor which promotes 
neovascularization through extension and growth of existing arterial and capillary networks.13 
Macrophages, in addition, infiltrating the wound after PMN, modulate the wound 
angiogenesis by releasing angiogenic factors such as fibroblast growth factor (FGF)-2 and 
VEGF.14 FGF-2, originally called basic FGF, is involved in angiogenesis as well as in 
granulation tissue formation.15 Whereas tissue hypoxia has been described as a potent 
stimulator for expression of VEGF proteins and their receptors by macrophages, FGF proteins 
are released secondary to cell damage.9,16 The von Willebrand Factor (vWF) is synthesised by 
and stored in endothelial cells.17 When released, vWF appears to mediate platelet aggregation 
and adhesion. CD 31 is also expressed in endothelial cells and therefore, 
immunhistochemistry for CD31 and vWF can be used for illustrating and counting 
microvessel density in biospies.16 
 As clinical observations and own previous investigations18 are suggesting accelerated 
granulation tissue formation and wound healing of traumatic soft tissue defects undergoing 
VAC™ treatment, the aim of this study was to determine the impact of VAC™ therapy versus 
alternative Epigard™ application on local inflammation in the management of traumatic 
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wounds. Specifically to measure wound cytokine levels of IL-6, IL-8, VEGF and FGF-2 and 
furthermore to assess for neovascularization in the two treatment groups. 
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Patients and Methods 
Patients and surgical management 
A total of 32 patients suffering from traumatic soft tissue injuries requiring temporary wound 
closure after surgical debridement were prospectively included in the study (9 females, 23 
males, mean age 46.3 years, range 17 – 82; Table 1). All patients were enrolled under consent 
guidelines approved by the Human Ethical Committee of the University of Zurich. Patients 
were all admitted to the investigator’s hospital Trauma Centre presenting with either isolated 
soft tissue injuries, compartment syndrome with or without underlying fracture or open 
fractures of the upper or lower extremities (Tables 2 and 3). Excluded from the study were 
polytraumatized patients (ISS > 16), patients suffering from major head, torso, pelvic and 
spinal trauma as well as patients with clinical signs of systemic or local infection during 
follow up. They were excluded in order to avoid confounding effects by systemic 
inflammation frequently found in these patients. After emergency surgical management 
including fasciotomies, soft tissue debridement and fracture stabilization as appropriate, soft 
tissue defects were covered using VAC™ (n = 16) or Epigard™ (n = 16) according to the on 
call surgeon’s choice. In these patients, primary closure of the wound could not be performed 
due to imminent compartment syndrome, skin defects after initial debridement or soft tissue 
conditions necessitating second look operations e.g. contaminated wounds and open fractures. 
When VAC-therapy was used, the polyurethane foam was cut and fixed to the wound edge 
using skin staples or sutures. It was then sealed with a transparent adhesive tape and 
continuous negative topical pressure of 125 mmHg was applied using a vacuum pump. When 
Epigard was applied, the dressing was cut and fixed to the wound edge using skin staples or 
sutures. This was covered using sterile gauze dressing and bandage which stayed intact until 
the next change of dressing. Patients were then transferred to the intensive care unit or 
surgical ward according to their general condition. Considering sterility, pain control, possible 
further soft tissue debridement and/or wound closure, changes of dressing were performed 
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exclusively in the operating room 48 to 96 hours either after the emergency operation or after 
previous change of dressing. Number and time-point of changes of dressing depended on 
previous soft tissue conditions as judged by the operating surgeon. Similarly, time and type of 
definitive wound closure (delayed primary suture, split thickness skin grafting or muscular 
flap followed by split thickness skin grafting) was determined according to the responsible 
surgeon’s assessment. Trauma management, emergency and follow up surgical procedures 
including soft tissue debridement and fracture fixation as well as wound closure by delayed 
primary suture and split thickness skin grafting were performed by experienced trauma 
surgeons from the author’s unit (n=3). If a muscular flap was considered, plastic surgeons 
were involved who also performed the procedure. 
 
Wound fluid and serum sampling 
At each removal of VAC™ or Epigard™ during change of dressing or before definitive 
wound closure, one wound fluid and one serum sample per patient was collected. A total of 
80 samples were obtained. Wound fluid samples were collected by squeezing the VAC™ 
sponge or the Epigard™ under sterile conditions. Samples were all collected into endotoxin 
free tubes (cryotubes, NUNC international). Serum and wound fluid samples were then 
centrifuged at 4000 rpm for 20 min at 4°C, aliquoted and stored at –80°C until further 
processing.  
 
Measurement of cytokines in wound fluid and serum samples 
The cytokines IL-6, IL-8, VEGF and FGF-2 were analyzed by specific enzyme linked 
immunosorbent assays (ELISA) using commercially available ELISA kits (R&D Systems, 
Abingdon, UK). 
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Histopathology and Immunohistochemistry of wound tissue biopsies 
In addition to wound fluid and serum collection, at the first removal of VAC™ or Epigard™ 
dressing, tissue biopsies and attached foam samples from the center of the wound were 
collected, fixed in buffered formaldehyde 4% and embedded in paraffin blocks. From each 
paraffin block 2µm thick slides were cut and stained with Hematoxylin-Eosin (H&E). Due to 
the typical cytomorphology of PMN and macrophages no special stains were needed for their 
identification. In order to count neovascularisation, immunohistochemistry for VEGF, vWF 
and CD31 was performed on paraffin sections of formalin fixed tissues, using a Ventana 
Benchmark automated staining system (Ventana Medical Systems, Tucson, Arizona). For 
antigen retrieval, slides were heated with cell conditioner 1 (standard procedure). Endogenous 
biotin was blocked with the appropriate kit. Primary polyclonal rabbit antibody against VEGF 
(Neomarkers Lab Vision, dilution 1:100) was then applied and revealed with the Ventana-Red 
enhanced detection kit. Slides were counterstained with hematoxylin prior to glass 
coverslipping. CD31 and vWF immunhistochemistry were performed as described above. 
Primary polyclonal rabbit antibody against vWF (Dako A/S, Glostrup, Denmark, dilution 
1:1000) and primary monoclonal mouse antibody against CD31 (Dako A/S Glostrup, 
Denmark, dilution 1:10) were used. 
 
Neovascularization after VAC™ and Epigard™ treatment 
VAC™ (n=5) and Epigard™ (n=5) wound biopsies were investigated by an experienced 
pathologist (D.M) blinded to the type of wound dressing. The number of vessels, highlighted 
by CD31 and vWF immunhistochemistry, was counted per 1mm2. When the vessel density in 
a biopsy was heterogeneous, always the area with the highest vessel density was chosen. For 
VEGF expression the whole biopsy was investigated semiquantitativly with a 3 point scoring 
system: score 1 little, score 2 moderate and score 3 severe VEGF expression.  
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Statistical analysis 
Data were analyzed for statistical significance using SigmaStat™ (SPSS Science Software 
GmbH, Erkrath, Germany). Treatment groups were compared statistically regarding gender 
distribution using the Fisher exact test, regarding age using the Student’s t-test and regarding 
ISS using the Mann-Whitney U test. For analysis of cytokine levels within the VAC™ or 
Epigard™ treatment group, one way (time) repeated measures ANOVA was used. As this 
revealed no significant changes in cytokine concentrations over time, patient’s means of 
cytokine levels during VAC™ versus Epigard™ therapy were compared and therefore, the 
Student’s t-test or, if normality test failed, the Mann-Whitney U test was applied. Vessel 
density and VEGF expression during VAC™ versus Epigard™ therapy were analyzed using 
the Student’s t-test and Mann-Whitney U test, respectively. A P level < 0.05 was considered 
statistically significant. 
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Results 
Cytokines in wound fluid and serum after VAC™ and Epigard™ treatment 
A total of 80 wound fluid and serum samples from 32 patients were analyzed and IL-6, IL-8, 
VEGF and FGF-2 concentrations were measured by ELISA. In 24 patients (VAC™ n = 11, 
Epigard™ n = 13) definitive wound closure was performed at the first change of dressing and 
one wound fluid and one serum sample per patient could be examined. Eight patients (VAC™ 
n = 5, Epigard™ n = 3) underwent one change of dressing before definitive wound closure 
and two consecutive wound fluid and serum samples were analyzed (Tables 2 and 3).  
 All cytokines were elevated in wound fluids at each removal of dressing during 
VAC™ therapy as well as Epigard™ treatment (Table 4). On the contrary, serum 
concentrations were negligible or not detectable during both treatments with VAC™ and 
Epigard™ (Table 4).  
 No statistically significant change of concentration over time could be detected in 
wound fluids during both VAC™ and Epigard™ therapy for any of the cytokines measured as 
assessed by one way repeated measures ANOVA. However, comparisons of patient’s mean 
cytokine concentrations in wound fluids revealed statistically significant higher IL-8 
(p<0.001; Table 4) and VEGF (p<0.05; Table 4) levels during VAC™ therapy compared with 
Epigard™ application. In contrast, a statistically significant difference between VAC™ and 
Epigard™ treatment was found neither for IL-6 and FGF-2 concentrations in wound fluids 
nor for any cytokine measured in serum.  
 
Local accumulation of PMN in wound tissue after VAC™ therapy 
Histological examination of wound ground biopsies with attached VAC™ foam showed 
visible higher accumulation of PMN (Figs. 2A and B) compared to wound ground biopsies 
with Epigard™ dressing (Figs. 2E and F). This is in accordance with the locally increased 
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levels of IL-8 in wound fluids during VAC™ therapy. In both treatment groups spare 
macrophages were identified. 
 
Increased expression of VEGF and corresponding augmented neovascularization in wound 
tissue after VAC™ therapy 
Wound biopsies treated with VAC™ therapy showed immunohistochemically visible higher 
expression of VEGF (Fig. 2C) compared to Epigard™ application (Fig. 2G), which is 
corroborated statistically by semiquantitative analysis (p<0.005). VEGF was mostly 
expressed in cells identified as PMN. 
In addition, vWF and CD31 immune staining, which visualizes small vessels, showed a 
statistical significant increased neovascularisation after VAC™ (33.6  2.9, mean  SEM) 
therapy (Fig. 2D) compared to Epigard™ (14.0  3.3) treatment (p<0.05) (Fig. 2H).  
 
Clinical outcome 
Clinical outcome parameters are presented in Tables 2 and 3. Although significantly higher 
cytokine levels, PMN accumulation as well as expression of VEGF and vWF could be shown 
during VAC™ therapy compared with Epigard™ application, clinical results were similar in 
both treatment groups showing no significant overall differences in closure time and hospital 
stay.  
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Discussion 
Although in clinical settings improved and accelerated granulation tissue formation and 
wound healing has been attributed to VAC™ therapy compared to alternative wound 
dressings such as Epigard™, the exact underlying mechanisms remain largely unknown. 
Experimental studies have previously shown that mechanical stress can induce tissue 
responses including cytokine release and cell proliferation.19-22 Thus, it can be hypothesized 
that VAC™ therapy may cause mechanically triggered immunomodulation as well as 
neovascularization and/or angiogenesis, finally leading to improved wound healing. In our 
present study, therefore, the impact of VAC™ therapy versus alternative Epigard™ 
application on local inflammation and neovascularization was assessed. The cytokines IL-6, 
IL-8, VEGF as well as FGF-2 were measured and compared in wound fluids and serum 
samples of 16 patients treated with VAC™ therapy and 16 patients treated with Epigard™ 
dressing for traumatic soft tissue injuries requiring temporary wound coverage (Tables 2 and 
3). Furthermore, wound biopsies were processed for histological examination. The specimens 
were evaluated as to the presence of PMN, VEGF expression and neovascularization.  
 In the present study, all the cytokines measured were elevated during the whole study 
period in wound fluids of both patient groups treated either with VAC™ or Epigard™, 
whereas serum concentrations remained at constant low levels. These findings are 
corroborated by a previous report of markedly higher cytokine and growth factor levels in 
wounds compared with serum in a clinical model of controlled operative plastic surgery 
trauma,3 indicating a compartmentalization of the immune response after local soft tissue 
injuries.  
 In response to traumatic injuries, IL-6 appears to play an active role in the post injury 
immune cascade.23 In local soft tissue injuries e.g. elective surgery, IL-6 serum levels were 
increased within 90 minutes of skin incision being elevated up to 72 hours before 
decreasing.23 This corroborates our presented results of low or not detectable IL-6 serum 
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levels measured at the first removal of dressing performed within 48 to 96 hours post-injury. 
In contrast to serum concentrations, however, we found IL-6 levels in wound fluids to be 
constantly elevated in all patients treated with VAC™ or Epigard™, indicating ongoing local 
inflammation independent from the type of dressing.  
 Similar to IL-6, FGF-2 levels did not differ in wound fluids of patients treated with 
VAC™ or Epigard™ and thus, indicating releasing mechanisms other than provoked by 
VAC™ therapy. Trengove et al. postulated that the highly proteolytic extracellular 
environment of chronic wounds may have direct effects on the levels of FGF, which is a 
matrix bound growth factor.24 Interestingly, in the same study a direct relationship between 
IL-6 and FGF was found which could explain our findings of comparable FGF-2 levels in 
wound fluids during both VAC™ and Epigard™ treatment. 
 In contrast to IL-6 as well as FGF-2, significantly higher local IL-8 concentrations 
were detected in wound fluids of patients during VAC™ therapy compared with Epigard™ 
application. The increased partial oxygen pressure in the local wound tissue during VAC™ 
therapy may be responsible for these several fold higher IL-8 levels during VAC™ therapy, 
as macrophages and endothelial cells upregulate IL-8 under this condition.25,26 Furthermore, 
increased IL-8 levels in wound fluids during VAC™ therapy accompanied by local 
accumulation of PMN, as demonstrated histolgically in this study, can explain clearance of 
local debris and contamination during VAC™ treatment,2 finally resulting in earlier and more 
reliable wound closure as previously reported.27  
 In severely ischemic and/or hypoxic wound conditions, increasing oxygen 
concentrations result in accelerated wound healing with increased blood vessel growth.28,29 In 
vitro studies demonstrated that hyperbaric oxygen leads to upregulation of platelet derived 
growth factor (PDGF) receptor in the presence of oxidants such as hydrogen peroxide, 
stimulating endothelial cells and keratinocytes to release VEGF.30,31 Similarly, an 
experimental wound model in rats showed increased VEGF levels of approximately 40% 
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under hyperbaric oxygen therapy.32 In addition, clinical and experimental studies have shown 
that mechanical stretch triggers VEGF secretion.33-35 Taken together, this supports our clinical 
findings of significantly higher VEGF levels in wound fluids during VAC™ therapy 
compared with Epigard™ application. Recent studies have demonstrated PMN and 
neutrophils in particular to express VEGF.11,12 Thus, the elevated local VEGF in wound fluids 
during VAC™ therapy in our study can be explained by increased and early accumulation of 
neutrophils as shown histologically. Elevated levels of VEGF were also demonstrated in our 
previous investigation where cytokines were measured in wound fluids of patients with 
traumatic wounds treated initially with Epigard followed by VAC therapy.18 These results 
prompted us to assess the initial impact of VAC versus Epigard treatment on cytokine 
levels in wound fluids and local early inflammation. In addition to PMN, macrophages are 
known to be a source of VEGF peaking around the fifth day after injury in wound 
infiltration.36 Interestingly, a more recent study also described an autocrine amplification 
mechanism for VEGF that induces chemotaxis of human neutrophils in extravascular tissue.37 
Finally, supported by our findings in wound biopsies of increased VEGF expression in PMN 
and presence of augmented small vessels during VAC™ treatment, it can be hypothesized 
that VAC™ therapy triggers neovascularization in traumatic soft tissue wounds.  
 The application of VAC™ as temporary wound coverage not only supports wound 
conditioning and facilitates definitive wound closure but also decreases frequency of dressing 
changes and risk of wound infection, offering considerable advantages regarding patient's 
comfort and hospital hygiene.2 VAC therapy has been described to be beneficial for the 
wound management in a variety of complex soft tissue conditions such as destruction of chest 
wall musculature from trauma, empyema of local infection as well as infected war time 
missile injuries.27,38,39 In contrast, our study could not reveal any significant difference 
regarding time point of definitive wound closure as well as hospital stay between patients 
receiving VAC™ therapy and patients treated with Epigard™. However, closure time as well 
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as hospital stay in particular are influenced by a variety of medical and non medical factors in 
these patients, and therefore, might not directly reflect advantages or disadvantages of any 
particular wound dressing. Thus, it can be hypothesized that the apparent positive effects of 
VAC therapy could be more accentuated in the treatment of other patients with more 
complex soft tissue wounds and therefore, additional clinical studies are necessary to further 
establish VAC™ therapy as a wound care modality.  
 These are the first data to demonstrate a selective and locally amplified humoral and 
cellular immune reaction as well as accelerated neovascularization during VAC™ therapy of 
traumatic soft tissue wounds compared with alternative Epigard™ application. However, 
further investigations are necessary in order to fully elucidate the exact mechanisms and 
kinetics of the wound healing process during VAC™ therapy.  
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Table 1: Demographic data and Injury Severity Score (ISS) of patients with traumatic wounds 
treated with VAC™ and Epigard™ 
 
 
 VAC™ Epigard™ 
Age1) 45  5.3 47  3.6 
Gender distribution2) 4 x female; 12 x male 5 x female; 11 x male 
ISS3) 7.9  0.8 9.6  1.0 
 
Basic demographic data and ISS of 32 patients with traumatic wound treated either with 
VAC™ (n = 16) or Epigard™ (n = 16) dressing. Values represent means ± SEM. 
 
1) P > 0.05 VAC™ versus Epigard™ (Student’s t-test) 
2) P > 0.05 VAC™ versus Epigard™ (Fisher exact test) 
3) P > 0.05 VAC™ versus Epigard™ (Mann-Whitney U test) 
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Table 2: Clinical data of patients treated with VAC™ 
 
patient n° type of injury 1) site mechanism 
n° of changes 
of dressing 
closure type closure time 2) hospital stay (days) 
1 soft tissue injury thigh knife stab wound 1 skin suture 4 7 
2 soft tissue injury thigh motorbike accident 2 split thickness skin graft 5 14 
3 soft tissue injury leg animal (boar) bite 1 skin suture 2 14 
4 soft tissue injury leg crushed between train and train platform 1 split thickness skin graft 3 9 
5 soft tissue injury elbow joint dislocation 1 muscular flap 11 36 
6 compartment syndrome leg gunshot injury 2 skin suture 4 9 
7 compartment syndrome leg sports injury (soccer) 1 skin suture 4 7 
8 compartment syndrome leg motorbike accident 1 skin suture 3 7 
9 compartment syndrome arm crushed by industrial machine 2 skin suture 6 10 
10 compartment syndrome/closed fracture leg/proximal tibia pushbike hit by car 2 split thickness skin graft 25 40 
11 compartment syndrome/closed fracture midfoot/forefoot hit by heavy plate at work 1 muscular flap 8 35 
12 open fracture (II) tibia and fibula motorbike accident 1 muscular flap 3 37 
13 open fracture (II) olecranon car accident 1 skin suture 2 9 
14 open fracture (III) calcaneus pushbike accident 1 muscular flap 6 46 
15 open fracture (III) humerus car accident 1 split thickness skin graft 2 15 
16 open fracture-dislocation (III) ankle crushed by heavy load at work 2 muscular flap 5 16 
1) Gustilo-Anderson40 classification of open wounds 
2) Days from first VACTM application to definitive wound closure 
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Table 3: Clinical data of patients treated with Epigard™ 
 
patient n° type of injury 1) site mechanism 
n° of changes 
of dressing 
closure type closure time 2) hospital stay (days) 
17 soft tissue injury leg /foot motorbike accident 1 muscular flap 8 6 
18 compartment syndrome thigh sports injury (skiing) 1 skin suture 3 20 
19 compartment syndrome leg pushbike accident 1 skin suture 5 13 
20 compartment syndrome leg pedestrian hit by car 1 skin suture 3 13 
21 compartment syndrome / closed fracture leg/proximal tibia car accident 1 split thickness skin graft 6 25 
22 compartment syndrome / closed fracture leg/proximal tibia fall from 2 meters 1 skin suture 6 38 
23 compartment syndrome / closed fracture leg/tibia and fibula pedestrian hit by motorbike 1 skin suture 5 19 
24 compartment syndrome / closed fracture leg/ankle simple fall 1 skin suture 7 16 
25 open fracture (II) tibia and fibula gunshot injury 1 split thickness skin graft 2 19 
26 open fracture (II) calcaneus crushed by industrial machine 1 muscular flap 8 33 
27 open fracture (III) distal femur hit by ruptured steel cable 1 muscular flap 4 37 
28 open fracture (III) tibia and fubula fall from 8 meters 2 split thickness skin graft 4 33 
29 open fracture-dislocation (III) ankle car accident 2 muscular flap 15 27 
30 open fracture-dislocation (III) ankle simple fall 1 split thickness skin graft 9 28 
31 open fracture (IIIC) distal femur gunshot injury 2 split thickness skin graft 16 30 
32 open fracture (IIIC) proximal tibia car accident 1 skin suture 4 (amputation) 16 
1) Gustilo-Anderson40 classification of open wounds (IIIC indicating major vascular injury) 
2) Days from 1st EpigardTM application to definitive wound closure 
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Table 4: Cytokine levels in wound fluids and serum during VAC™ and Epigard™ therapy of patients with traumatic soft tissue injuries.  
 
wound fluid serum  
VAC™ Epigard™ P value VAC™ Epigard™ P value 
IL-6 3 36999.4 ± 15735.7 
57246.8 ± 
38955.5 P = 0.397 not detectable 20.1 ± 18.0 not determined 
IL-8 3 407.9 ± 175.5 56.4 ± 11.4 P < 0.001 17.1 ± 8.6 10.0 ± 6.8 P = 0.927 
VEGF [pg/ml] 8396.5± 762.7 5364.4 ± 695.0 P = 0.006 584.3 ± 105.2 572.8 ± 95.9 P = 0.936 
FGF-2 [pg/ml] 361.9 ± 43.9 452.4 ± 76.9 P = 0.272 83.6 ± 48.7 65.3 ± 35.0 P = 0.983 
 
32 Patients with traumatic wounds were treated either with VAC™ (n = 16) or Epigard™ (n =16) dressing. At each removal of VAC™ or 
Epigard™ during change of dressing or before definitive wound closure, one sample of wound fluid and serum per patient were collected. A total of 
80 samples were collected (VAC™ n = 42; Epigard™ n = 38). Cytokines were measured by ELISA. As repeated measures ANOVA revealed no 
significant change of cytokine concentrations over time, values represent means of patient’s means ± SEM.  
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Figure 1 
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Figure 2 
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Figure Legend 
Figure 1 
Clinical pictures of traumatic wounds treated either with Epigard™ dressing (A) or Vacuum-
Assisted Closure (VACTM) therapy (B). 32 Patients were admitted to the investigator’s 
hospital Trauma Centre presenting with either isolated soft tissue injuries, compartment 
syndrome with or without underlying fracture, open fractures or traumatic amputation of the 
upper or lower extremities. After emergency surgical management including fasciotomies, 
soft tissue debridement and fracture stabilization as appropriate, soft tissue defects were 
covered using Epigard™ (A) or VAC™ (B). 
 
Figure 2 
Representative tissue biopsies of patients with traumatic soft tissue injuries treated either with 
VAC™ (A, B, C and D, patient number 12 in Table 2, 72 hours after initial VAC 
application) or Epigard™ (E, F, G and H, patient number 25 in Table 3, 48 hours after initial 
Epigard application). Biopsies with attached foam samples from the center of the wound 
were collected at the first removal of VAC or Epigard dressing 48 to 96 hours after the 
emergency operation as described in detail in Patients and Methods. A: Overview. VAC™ 
foam with accumulation of polymorphonuclear neutrophils (PMN), Hematoxylin&Eosin 
(H&E), x75. B (including inset) and C: Magnification of picture A. B: H&E, x300; inset: 
PMN, H&E, x400. C: High expression of vascular endothelial growth factor (VEGF), x300. D 
and H: Wound tissue with high neovascularisation in VAC™ patients (D) compared to low 
neovascularisation in Epigard™ patients, CD31, x75. E: Overview. Wound coverage with 
Epigard™ and few PMN, H&E, x75. F and G: Magnification of picture E. F: H&E, x300. G: 
Low expression of VEGF, x300. 
 
 
